A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient
- Conditions
- HIV Infections
- Registration Number
- NCT00002184
- Lead Sponsor
- Gilead Sciences
- Brief Summary
To evaluate the safety and tolerance of the combination of adefovir dipivoxil at two comparative doses and nelfinavir plus saquinavir SGC administered orally (Group 1) vs. the combination of adefovir dipivoxil and nelfinavir plus either zidovudine, lamivudine, or stavudine (Group 2) vs. the combination of adefovir dipivoxil and saquinavir SGC plus either zidovudine, lamivudine, or stavudine (Group 3) in HIV-infected patients with prior nucleoside reverse transcriptase inhibitor therapy but no prior exposure to protease inhibitors who have CD4 cell counts \>= 100 cells/mm3 and an HIV-1 RNA baseline copy number \>= 5000 copies/ml. To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (\<500 copies/ml) at 20 weeks of study therapy and the average reduction in HIV-1 RNA from baseline through study week 20. To evaluate the durability of the antiviral response through 48 weeks of study in patients who continue on study therapy after week 24.
- Detailed Description
This protocol is a stratified, randomized, double-blind, dose-comparative study of the safety and efficacy of adefovir dipivoxil in combination with nelfinavir and saquinavir soft gel capsules (SGC) or adefovir dipivoxil in combination with nelfinavir or saquinavir SGC plus a nucleoside analog (zidovudine, lamivudine, or stavudine).
Patients will be randomized to adefovir dipivoxil with nelfinavir and saquinavir or adefovir dipivoxil with nelfinavir or saquinavir plus a nucleoside analog (zidovudine, lamivudine, or stavudine). Within each treatment arm, patients will be randomized to 1 of 2 doses of adefovir dipivoxil in a blinded manner. Patients randomized to receive a nucleoside analog will then be assigned to receive either zidovudine, lamivudine, or stavudine based upon their previous RTI therapy. A daily dose of L-carnitine will be administered to all patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (15)
Krauss Med Partners / Dept of Research and Development
🇺🇸Los Angeles, California, United States
UCLA Care Ctr
🇺🇸Los Angeles, California, United States
Hosp Regional de Ponce - Area Vieja
🇵🇷Ponce, Puerto Rico
San Juan AIDS Program
🇵🇷Santruce, Puerto Rico
Associates of Med and Mental Health
🇺🇸Tulsa, Oklahoma, United States
Davies Med Ctr
🇺🇸San Francisco, California, United States
Blick Med Associates
🇺🇸Greenwich, Connecticut, United States
Phoenix Body Positive
🇺🇸Phoenix, Arizona, United States
Johns Hopkins Univ School of Medicine
🇺🇸Baltimore, Maryland, United States
Univ of Texas Southwestern Med Ctr of Dallas
🇺🇸Dallas, Texas, United States
Univ of Massachusetts Med Ctr
🇺🇸Worcester, Massachusetts, United States
Univ of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Mem Hosp of Rhode Island
🇺🇸Pawtucket, Rhode Island, United States
George Washington Med Ctr
🇺🇸Washington, District of Columbia, United States
North Shore Community Hosp
🇺🇸Manhassett, New York, United States